Century Therapeutics Inc.

0.53
-0.01 (-1.85%)
At close: Apr 24, 2025, 3:59 PM
0.53
-1.00%
Pre-market: Apr 25, 2025, 07:01 AM EDT

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.

Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics Inc.
Century Therapeutics Inc. logo
Country United States
IPO Date Jun 18, 2021
Industry Biotechnology
Sector Healthcare
Employees 140
CEO Dr. Morgan Conn Ph.D.

Contact Details

Address:
3675 Market Street
Philadelphia, Pennsylvania
United States
Website https://www.centurytx.com

Stock Details

Ticker Symbol IPSC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001850119
CUSIP Number 15673T100
ISIN Number US15673T1007
Employer ID 84-2040295
SIC Code 2836

Key Executives

Name Position
Dr. Morgan Conn Ph.D. Chief Financial Officer

Latest SEC Filings

Date Type Title
Apr 22, 2025 ARS Filing
Apr 22, 2025 DEFA14A Filing
Apr 22, 2025 DEF 14A Filing
Mar 20, 2025 S-8 Filing
Mar 19, 2025 8-K Current Report
Mar 19, 2025 10-K Annual Report
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing